KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis. PMID 38291376 · BMC Cancer · 2024-Jan-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. PMID 38290766 · J Immunother Cancer · 2024-Jan-30 Study is a single-arm, open-label, phase IIIb trial, not a randomized trial. It meets oncology, human, drug intervention, and time-to-event criteria, but fails the randomized requirement.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of AI-aided colonoscopy in clinical practice: a prospective randomised controlled trial. PMID 38290758 · BMJ Open Gastroenterol · 2024-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ENABLE-SG (Educate, Nurture, Advise, Before Life Ends for Singapore) as a proactive palliative care model: protocol for a hybrid type 1 effectiveness-implementation randomized wait-list controlled trial. PMID 38287335 · BMC Palliat Care · 2024-Jan-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study. PMID 38399512 · Medicina (Kaunas) · 2024-Jan-28 未发现恶性肿瘤人群证据。
H B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
New First-line Immunotherapy-based Therapies for Unresectable Hepatocellular Carcinoma: A Living Network Meta-analysis. PMID 38250466 · J Clin Transl Hepatol · 2024-Jan-28 This is a network meta-analysis that synthesizes results from multiple Phase III trials, not an original report of a single randomized trial. The required criterion of being an 'original formal-result report of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial' is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of a novel pain management device, AT-04, for endometriosis-related pain: study protocol for a phase III randomized controlled trial. PMID 38279180 · Reprod Health · 2024-Jan-26 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. PMID 38279087 · BMC Cancer · 2024-Jan-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Testing the feasibility of a co-designed intervention, comprising self-managed, home-based, exercise training with embedded behavioural support and compression therapy for people with venous leg ulcers receiving treatment at home (FISCU-II). PMID 37819015 · Clin Exp Dermatol · 2024-Jan-25 Study is not oncology-focused; it examines venous leg ulcers, a non-malignant condition. The intervention is exercise/behavioral support plus compression (non-drug), and the primary endpoint is feasibility, not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quantifying the carbon footprint of clinical trials: guidance development and case studies. PMID 38267250 · BMJ Open · 2024-Jan-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study. PMID 37738088 · Blood Adv · 2024-Jan-23 The record is an original Phase III clinical trial with drug intervention and primary time-to-event endpoints, but the abstract does not explicitly state that patients were randomly assigned to the two conditioning regimens. The deterministic review also flagged insufficient evidence for randomization. Therefore, it does not meet all required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The feasibility of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer, prior to the CanMoRe trial. PMID 38254174 · Pilot Feasibility Stud · 2024-Jan-22 This is a feasibility study for a future randomized controlled trial, not a definitive trial with results. It is not Phase III/IIIb or Phase II/III, does not involve a drug intervention, and has no time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). PMID 37931206 · J Clin Oncol · 2024-Jan-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. PMID 37883723 · J Clin Oncol · 2024-Jan-20 The record describes a randomized, oncology, human trial with drug interventions and time-to-event endpoints, but the provided metadata does not explicitly establish the trial phase as Phase III, IIIb, or Phase II/III. As per adjudication rules, metadata must explicitly establish the phase without inference.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Broad-spectrum antibiotic prophylaxis in tumor and infected orthopedic surgery-the prospective-randomized, microbiologist-blinded, stratified, superiority trials: BAPTIST Trials. PMID 38243311 · Trials · 2024-Jan-19 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Optimizing the use of ketamine to reduce chronic postsurgical pain in women undergoing mastectomy for oncologic indication: study protocol for the KALPAS multicenter randomized controlled trial. PMID 38243266 · Trials · 2024-Jan-19 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Development and validation of nomogram for predicting early recurrence after radical gastrectomy of gastric cancer. PMID 38243254 · World J Surg Oncol · 2024-Jan-19 Study is a retrospective cohort analysis developing a predictive nomogram for early recurrence after surgery. It is not a randomized trial, does not test a drug intervention, and does not report time-to-event efficacy endpoints like OS/PFS/DFS with Kaplan-Meier or HR.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Increasing access to fertility preservation for women with breast cancer: protocol for a stepped-wedge cluster randomized trial in France. PMID 38243214 · BMC Public Health · 2024-Jan-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. PMID 38242720 · J Immunother Cancer · 2024-Jan-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. PMID 38233100 · J Immunother Cancer · 2024-Jan-17 The record describes a systematic comparison of efficacy results (ORR) between early-phase and Phase III trials. While it involves Phase III trial data, it is a meta-analytic study comparing ORR, which is not a time-to-event endpoint. The required primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, with Kaplan-Meier or HR) is absent.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. PMID 37966367 · Clin Cancer Res · 2024-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma. PMID 37676259 · Clin Cancer Res · 2024-Jan-17 The record is an FDA Approval Summary, which is an editorial/regulatory report summarizing the HIMALAYA trial results, not the primary research article presenting the original trial data. While the underlying trial meets most criteria, this specific report is not the original result publication. Additionally, the trial phase is not explicitly stated in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma. PMID 37610803 · Clin Cancer Res · 2024-Jan-17 This is a primary result report of a randomized trial evaluating a drug combination for a human malignant neoplasm (pediatric low-grade glioma with BRAFV600E mutation), meeting all core eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Bowel preparation protocol for hospitalized patients ages 50 years or older: A randomized controlled trial. PMID 38313462 · World J Gastrointest Endosc · 2024-Jan-16 The study is a randomized controlled trial in humans, but it is not an oncology trial focused on cancer treatment. The intervention is a bowel preparation regimen for colonoscopy, not a drug for cancer therapy. The primary endpoint is bowel cleansing adequacy (a non-cancer, non-time-to-event outcome), and there is no mention of survival, progression-free survival, or other time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. PMID 38227033 · JAMA · 2024-Jan-16 The record is a randomized clinical trial in oncology (NSCLC) with a drug intervention, reporting primary time-to-event efficacy (EFS with HR) from an interim analysis. The trial is pivotal/definitive for a perioperative indication, meeting Phase III/IIIb or Phase II/III criteria. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 3 Panel · risk visible
Extraperitonealization of the ileal conduit decreases the risk of parastomal hernia: A single-center, randomized clinical trial. PMID 38154462 · Cell Rep Med · 2024-Jan-16 The study is an original, randomized, Phase II-equivalent trial for human oncology (bladder cancer) with a primary time-to-event endpoint. However, it is excluded because the intervention is a surgical technique, not a drug-containing intervention as required by the cohort definition.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. PMID 38225589 · BMC Cancer · 2024-Jan-15 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study. PMID 38225579 · Trials · 2024-Jan-15 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of a one-year supervised physical activity program on long-term cancer-related fatigue and mediating effects of the gut microbiota in metastatic testicular cancer patients: protocol of the prospective multicentre, randomized controlled phase-III STARTER trial. PMID 38225551 · BMC Cancer · 2024-Jan-15 This is a protocol for a phase-III randomized trial in metastatic testicular cancer patients receiving chemotherapy, but it does not present results. The primary endpoint is cancer-related fatigue (a patient-reported outcome), and there is no explicit mention of a time-to-event efficacy endpoint (like OS, PFS, DFS) or Kaplan-Meier/HR analysis. Therefore, it does not meet the criteria for a result report with a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Precutting endoscopic band ligation-assisted resection versus endoscopic submucosal dissection in patients with small gastric submucosal tumors originating from the muscularis propria: study protocol of a randomized controlled trial. PMID 38218850 · Trials · 2024-Jan-13 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. PMID 38104577 · Lancet · 2024-Jan-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial. PMID 38217032 · Trials · 2024-Jan-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) - protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. PMID 38216200 · BMJ Open · 2024-Jan-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Home-based cognitive bias modification training for reducing maladaptive fear in patients with suspected acute coronary syndrome: a pilot randomized clinical trial. PMID 38212853 · Pilot Feasibility Stud · 2024-Jan-11 The study is a pilot randomized clinical trial of a cognitive bias modification training intervention for patients with suspected acute coronary syndrome. It is not an oncology trial, does not involve a drug intervention, and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Insignificant influence of the intertransverse process block for major breast cancer surgery: a randomized, blinded, placebo-controlled, clinical trial. PMID 37169487 · Reg Anesth Pain Med · 2024-Jan-11 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial. PMID 38200410 · BMC Cancer · 2024-Jan-10 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial. PMID 37922442 · J Clin Oncol · 2024-Jan-10 Meets all required criteria: oncology, human, randomized, definitive trial phase, drug intervention, time-to-event primary/secondary endpoints, and original final result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Autogenic splenic implantation versus splenectomy in patients undergoing distal pancreatectomy for benign or low-grade malignant lesions of the distal pancreas: study protocol for a multicentre, open-label, randomized controlled trial (RESTORE). PMID 38195501 · Trials · 2024-Jan-09 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Early detection of clinically significant prostate cancer: protocol summary and statistical analysis plan for the ProScreen randomised trial. PMID 38195170 · BMJ Open · 2024-Jan-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial. PMID 38194162 · Support Care Cancer · 2024-Jan-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mini-AFTERc: a controlled pilot trial of a nurse-led psychological intervention for fear of breast cancer recurrence. PMID 38191445 · Pilot Feasibility Stud · 2024-Jan-08 This is a non-randomized, pilot feasibility study of a psychological intervention for fear of breast cancer recurrence. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention, and it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic significance of surgery and radiotherapy in elderly patients with localized prostate cancer: establishing and time-based external validation a nomogram from SEER-based study. PMID 38184526 · BMC Urol · 2024-Jan-06 This is a retrospective, SEER-based registry study (a nomogram development and validation study) evaluating prognostic factors for survival in prostate cancer patients. While it uses a randomized data split for model training/validation, it is not a randomized clinical trial (RCT). The 'Randomized Controlled Trial' publication type is a misclassification. The study lacks a drug intervention and does not report results from a Phase III/IIIb or Phase II/III randomized drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effects of high-intensity interval training and Iranian propolis extract on serum levels of TRPV4 and CYP2E1 proteins in patients with nonalcoholic fatty liver. PMID 38545725 · Tunis Med · 2024-Jan-05 The study is a randomized controlled trial in humans with a drug intervention (propolis), but it is not an oncology study (focuses on non-alcoholic fatty liver disease, not cancer), lacks Phase III or definitive Phase II/III trial designation, and does not report a time-to-event efficacy endpoint. Therefore, it does not meet eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial. PMID 38183137 · Trials · 2024-Jan-05 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparative analysis of radiomics and deep-learning algorithms for survival prediction in hepatocellular carcinoma. PMID 38182664 · Sci Rep · 2024-Jan-05 The study is an original, retrospective analysis of imaging algorithms for survival prediction in HCC. While it involves human subjects, is oncology-focused, includes a time-to-event endpoint (OS), and uses a randomized data split, it lacks a drug-containing intervention and is not a Phase III/IIIb or Phase II/III randomized trial evaluating a therapeutic drug. The publication type is listed as 'Randomized Controlled Trial', but the abstract describes a methodological study, not a clinical trial of a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials. PMID 38182614 · Sci Rep · 2024-Jan-05 The record is a pooled secondary analysis examining the association of proton pump inhibitor use with outcomes across three randomized trials. It is not the original primary result report of a single Phase III/IIIb or Phase II/III randomized trial. The phase of the underlying trials is not specified, and the analysis itself is a secondary, non-primary study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic factors and constructing a nomogram in tracheal cancer patients treated with surgical intervention: A study based on SEER database. PMID 38181293 · Medicine (Baltimore) · 2024-Jan-05 The study is an oncology human retrospective analysis from a database (SEER) that develops a prognostic nomogram for tracheal cancer patients treated with surgery. While it uses Kaplan-Meier survival curves and is described as having randomized cohort splitting, it is not a prospective randomized controlled trial testing a drug intervention. It lacks Phase III/IIIb or Phase II/III evidence and a drug-containing intervention, which are required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients. PMID 37906649 · Clin Cancer Res · 2024-Jan-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Self-sampling tools to increase cancer screening among underserved patients: a pilot randomized controlled trial. PMID 38060284 · JNCI Cancer Spectr · 2024-Jan-04 The record is a pilot randomized trial assessing self-sampling tools for cancer screening uptake, not a Phase III/IIIb or Phase II/III trial evaluating a drug intervention with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. PMID 37647633 · Blood · 2024-Jan-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -